AAPL   318.35 (+0.03%)
FB   227.22 (+0.78%)
GOOGL   1,428.35 (+0.71%)
AMZN   2,422.41 (+0.89%)
NVDA   344.84 (+1.58%)
CGC   17.86 (-17.77%)
MU   46.72 (+0.54%)
GE   6.65 (-2.06%)
TSLA   811.48 (+0.70%)
AMD   52.51 (+1.49%)
ACB   14.27 (-6.98%)
GILD   75.25 (-0.09%)
DIS   116.37 (-0.33%)
BA   146.48 (-2.23%)
AAPL   318.35 (+0.03%)
FB   227.22 (+0.78%)
GOOGL   1,428.35 (+0.71%)
AMZN   2,422.41 (+0.89%)
NVDA   344.84 (+1.58%)
CGC   17.86 (-17.77%)
MU   46.72 (+0.54%)
GE   6.65 (-2.06%)
TSLA   811.48 (+0.70%)
AMD   52.51 (+1.49%)
ACB   14.27 (-6.98%)
GILD   75.25 (-0.09%)
DIS   116.37 (-0.33%)
BA   146.48 (-2.23%)
AAPL   318.35 (+0.03%)
FB   227.22 (+0.78%)
GOOGL   1,428.35 (+0.71%)
AMZN   2,422.41 (+0.89%)
NVDA   344.84 (+1.58%)
CGC   17.86 (-17.77%)
MU   46.72 (+0.54%)
GE   6.65 (-2.06%)
TSLA   811.48 (+0.70%)
AMD   52.51 (+1.49%)
ACB   14.27 (-6.98%)
GILD   75.25 (-0.09%)
DIS   116.37 (-0.33%)
BA   146.48 (-2.23%)
AAPL   318.35 (+0.03%)
FB   227.22 (+0.78%)
GOOGL   1,428.35 (+0.71%)
AMZN   2,422.41 (+0.89%)
NVDA   344.84 (+1.58%)
CGC   17.86 (-17.77%)
MU   46.72 (+0.54%)
GE   6.65 (-2.06%)
TSLA   811.48 (+0.70%)
AMD   52.51 (+1.49%)
ACB   14.27 (-6.98%)
GILD   75.25 (-0.09%)
DIS   116.37 (-0.33%)
BA   146.48 (-2.23%)
Log in

LON:ABZAABZENA/PAR VTG FPD 0.002 Share Price, Forecast & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average Volume26,706 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Abzena plc provides services and technologies for the selection, development, and manufacture of biopharmaceutical products in North America, Europe, and internationally. Its technologies include antibody drug conjugate (ADC) linker, antibody humanization, and protein deimmunisation. It provides phage display, Hybridoma sequencing, and developability assessment solutions for the discovery, isolation, development, and selection of antibodies; immunogenicity assessment and custom assays, as well as Cytokine Screen, an in vitro assay to evaluate the risk of biopharmaceutical products causing cytokine storm prior to it being progressed into clinical development. It also offers antibody and protein engineering solutions, which cover Ig class and isotype switching, antibody reformatting and humanization, protein deimmunisation, affinity maturation, antibody and protein production, and bioassays and bioanalytics; and ADCs, such as cysteine and lysine conjugation solutions, as well as ThioBridge, a disulfide rebridging conjugation technology. In addition, it provides solutions in the area of bioassays, which cover drug-conjugate and payload characterization, binding and competition assays, cell health assays, functional assays, Fc binding and function assays, and bespoke assay development; bioanalytics that cover candidate selection, biosimilarity, protein and peptide identification, ADC characterization, and analytical method development; peptide synthesis, modifications, and analytics; mammalian manufacturing, which cover cell line, process, and analytical development, as well as cell banking; peptide synthesis, modifications, and analytics; bioconjugates and ADCs manufacturing; and custom, library, HPAPI, and payload synthesis. Further, it offers full-time equivalent and protein/BioNMR services; and analytical solutions. It serves biopharmaceutical companies and academic groups. Abzena plc was incorporated in 2014 and is headquartered in Cambridge, the United Kingdom.
Read More
ABZENA/PAR VTG FPD 0.002 logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.58 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-1223-903498

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive ABZA News and Ratings via Email

Sign-up to receive the latest news and ratings for ABZA and its competitors with MarketBeat's FREE daily newsletter.

ABZENA/PAR VTG FPD 0.002 (LON:ABZA) Frequently Asked Questions

Has ABZENA/PAR VTG FPD 0.002 been receiving favorable news coverage?

Media stories about ABZA stock have trended extremely negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. ABZENA/PAR VTG FPD 0.002 earned a coverage optimism score of -4.8 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutABZENA/PAR VTG FPD 0.002.

Who are some of ABZENA/PAR VTG FPD 0.002's key competitors?

What other stocks do shareholders of ABZENA/PAR VTG FPD 0.002 own?

Who are ABZENA/PAR VTG FPD 0.002's key executives?

ABZENA/PAR VTG FPD 0.002's management team includes the following people:
  • Dr. William John Edward Burt, CEO & Exec. Director (Age 50)
  • Prof. Sunil Shaunak, Co-Founder & Chairman of the Scientific Advisory Board
  • Dr. Antony Godwin Ph.D., Co-Founder
  • Prof. Steve Brocchini Ph.D., Co-Founder
  • Dr. Jim Mills, Sr. VP of Technical Operations

What is ABZENA/PAR VTG FPD 0.002's stock symbol?

ABZENA/PAR VTG FPD 0.002 trades on the London Stock Exchange (LON) under the ticker symbol "ABZA."

How do I buy shares of ABZENA/PAR VTG FPD 0.002?

Shares of ABZA and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is ABZENA/PAR VTG FPD 0.002's official website?

The official website for ABZENA/PAR VTG FPD 0.002 is www.abzena.com.

How can I contact ABZENA/PAR VTG FPD 0.002?

ABZENA/PAR VTG FPD 0.002's mailing address is Babraham Hall, Babraham Research, CAMBRIDGE, CB22 3AT, United Kingdom. The company can be reached via phone at +44-1223-903498.

This page was last updated on 5/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.